About Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
Thermo Fisher Scientific Inc (TMO) is a Healthcare company in the Diagnostics & Research industry with a market capitalisation of $242.2B. The stock trades at 35.54x trailing earnings and yields 0.29%.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Market cap
- $242.2B
- P/E ratio
- 35.54
- Forward P/E
- 23.78
- EPS (TTM)
- $18.43
- Revenue (TTM)
- $46.3B
- Free cash flow
- $6.2B
- Profit margin
- 15.0%
- Dividend yield
- 0.29%
- Beta
- 0.85
- Shares outstanding
- 369.7M
Financial health: Strong7.7/10
6 strengths, 0 concerns. No red flags against these benchmarks.
- Debt to equity: 0.73 (Watch, benchmark < 0.5) — Debt of 0.73x equity is moderate against the 0.5x benchmark. It has been broadly flat over the last 4 years.
- Net debt vs cash flow: 4.6y (Watch, benchmark < 4 years) — Net debt of $29.1B is 4.6x annual free cash flow — about 5 years of cash flow to repay.
- Current ratio: 1.89 (Strong, benchmark > 1.5) — Short-term assets cover 1.89x short-term liabilities, against Graham's 1.5x floor. It has improved over the last 4 years.
- Return on equity: 13.5% (Watch, benchmark > 15%) — Earns 13.5% on shareholder equity, short of the > 15% mark.
- Gross margin: 41.0% (Strong, benchmark > 40%) — Keeps 41.0% of revenue after the direct cost of sales, comfortably past the > 40% mark.
- Net margin: 15.0% (Strong, benchmark > 10%) — Turns 15.0% of revenue into profit, comfortably past the > 10% mark.
- Free cash flow: $6.3B (Strong, benchmark positive) — Generated $6.3B of free cash flow after capital spending. It has been broadly flat over the last 4 years.
- Revenue growth: 10.5% (Strong, benchmark > 10%) — Revenue changed 10.5% year on year, comfortably past the > 10% mark.
- Earnings growth: 9.4% (Watch, benchmark > 10%) — Earnings changed 9.4% year on year, short of the > 10% mark.
- PEG ratio: 1.98 (Watch, benchmark < 1) — At 1.98, the price looks fair relative to expected growth — Lynch treated 1.0 as fair value.
- Payout ratio: 9.7% (Strong, benchmark < 60%) — Pays out 9.7% of earnings as dividends, leaving room to keep paying.